Original Article
Survey of Primary Care Physicians on Therapeutic Approaches to Lung and Breast Cancers
Abstract
Background: Primary care physicians (PCPs) are an important part of the decision-making process in the care of patients with cancer. The survey discussed herein evaluates what percentage of academic and community PCPs recognize benefits from systemic therapy in lung and breast cancers.Methods: PCPs were surveyed regarding their beliefs toward systemic therapy in early- and late-stage lung and breast cancers and were asked to rate the importance of specific factors that influence their referral decisions.
Results: A total of 3444 surveys were distributed, and 316 physicians (9.1%) responded: 89 academic physicians (28%) and 227 nonacademic physicians (72%). The rate of returned surveys was equal by specialty. A total of 57%, 42.1% in lung cancer and 72.6 % in breast cancer ( P < 0.001) of PCPs, believe in the curative effect of systemic therapy in early stages. Sixty-six percent (58.2% in lung cancer and 75.5% in breast cancer [ P < 0.001]) believe in improved disease-free survival. Although 82% believe that systemic therapy can prevent symptoms and prolong life in advanced asymptomatic disease, half (lung cancer 50.8%, breast cancer 53.1% [ P = 0.5]) of the PCPs would refer symptomatic patients with advanced disease to palliative care before referral to an oncologist. The type and stage of cancer, as well as the patient’s desire or reluctance to be referred to an oncologist were rated by PCPs as the most important reasons to refer patients to an oncologist ( P < 0.0001).
Conclusions: Although a majority of PCPs in academia and the community acknowledge the positive effect of chemotherapy, the benefit of systemic therapy for early-stage lung cancer is less appreciated as compared with breast cancer. Patients’ preferences influence PCPs significantly in the decision to refer patients to an oncologist.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Torring ML, Frydenberg M, Hansen RP, et al. Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer 2011;104:934-940.
3. Lyratzopoulos G, Neal RD, Barbiere JM, et al. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. Lancet Oncol 2012;13:353-365.
4. Yu S, Shabihkhani M, Yang D, et al. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer 2013;12:275-279.
5. Richards MA, Westcombe M, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119-1126.
6. Macleod U, Mitchell ED, Burgess C, et al. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer 2009;101:S92-S101.
7. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002;20:1786-1792.
8. Jennens RR, de Boer R, Irving L, et al. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 2004;126:1985-1993.
9. Piga A, Graziano F, Zahra G, et al. Attitudes of non-oncology physicians dealing with cancer patients. A survey based on clinical scenarios in Ancona province, central Italy. Tumori 1996;82:423-429.
10. Wassenaar TR, Elckhoff JC, Jarzemsky DR, et al. Differences in primary care clinicians’ approach to non-small cell lung cancer patients compared with breast cancer. J Thorac Oncol 2007;2:722-728.
11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
12. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005;93:293-301.
13. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2010: CD007309.
14. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
15. Sussman J, Baldwin LM. The interface of primary and oncology specialty care: from diagnosis through primary treatment. J Natl Cancer Inst Monogr 2010;2010:18-24.
16. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
17. Mosunjac M, Park J, Strauss A, et al. Time to treatment for patients receiving BCS in a public and a private university hospital in Atlanta. Breast J 2012;18:163-167.
18. Owusu C, Studenski SA. Shared care in geriatric oncology: primary care providers’ and medical/oncologist’s perspectives. J Am Geriatr Soc 2009;57:S239-S242.
